NASDAQ$MBX

MBX Biosciences Inc · Q4 2026 earnings

Q4 2026 earnings · · Before market open

Briefing

MBX Biosciences reported no product revenue, a Q1 2026 net loss of $23.5M, and diluted loss per share of $0.50.

Pre-revenue biotech MBX had no product sales. Net loss was $23.5 million, roughly flat vs. prior year; diluted loss per share was $0.50. Cash and marketable securities of about $440 million support clinical programs including canvuparatide.

  • No product revenue; net loss $(23.5)M.
  • Diluted EPS $(0.50).
  • Cash ~$440M runway.
  • Clinical-stage pipeline (canvuparatide, imapextide).

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.50

No prior period
Net Income

-$23.5M

No prior period
Operating Income

-$27.3M

No prior period

Revenue & EPS history

MBX Biosciences Inc · Revenue · Quarterly

$0

Q4 2026

Forward guidance

Development milestones are the forward focus; no commercial revenue guide.

Tailwinds

  • Strong liquidity vs. burn.
  • Stable quarterly loss.

Headwinds

  • No near-term product revenue.
  • Trial execution risk.

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro